Kazia Therapeutics Limited ("Kazia" or the "Company"), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the first patient ...

Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On June 5, 2025, Kazia Therapeutics announced the dosing of the first patient in a Phase ...

Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

A 24-year-old man presented with a 7-year history of recurrent melena, acutely worsening 3 days prior. He had undergone ...

Anti-aging aficionados have tried it all — including taking certain drugs off-label in the hopes they will lead to longer, ...

Clinically Balanced Essential Amino Acid Formula Helps Rebuild Strength, Energy, and Muscle Maintenance-Even as Protein ...

A combination of human anti-cancer drugs has been shown to increase the lifespan of mice by nearly 30%. This discovery opens ...

Abstract:        Obesity, a growing global issue, has been closely associated with an increased risk of various cancers, especially breast cancer. El ...

Identifying proteomic signatures of insulin resistance in fasting muscle offers insights for personalized type 2 diabetes ...

Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of ...

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that Professor Nahshon Knoller M.D., senior clinical advisor to the Company, will be ...